Evidence map›Paper›PMID 27638875›Full record

ArticleCancer research2016

Commentary on Almassalha et al., "The Greater Genomic Landscape: The Heterogeneous Evolution of Cancer".

Henry T Lynch, Marc Rendell, Trudy G Shaw, Peter Silberstein, Binh T Ngo

Abstract readComment
PubMed Publisher
In one paragraph

Article in Cancer research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Henry T LynchDepartment of Preventive Medicine, Creighton University, Omaha, Nebraska. htlynch@creighton.edu.
Marc RendellDepartment of Internal Medicine, Creighton University School of Medicine and the Rose Salter Medical Research Foundation, Omaha, Nebraska.
Trudy G ShawDepartment of Preventive Medicine, Creighton University, Omaha, Nebraska.
Peter SilbersteinDepartment of Hematology & Oncology, Creighton University, Omaha, Nebraska.
Binh T NgoDepartment of Dermatology, Keck USC School of Medicine and the Hoag-USC Advanced Skin Cancer Program, Los Angeles, California.
Creighton University · USCHI Health Creighton University Medical Center - Bergan Mercy · USKeck Hospital of USC · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this issue of Cancer Research, Almassalha and colleagues have proposed a new concept of the development of malignancy, that of the greater genomic landscape. They propose a stressor-related exploration of intracellular genomic sites as a response mechanism. This process can express sites with beneficial or deleterious effects, among them those that promote cell proliferation. They point out that their conception is broader, although certainly inclusive, of the process of gene induction. The authors view the physical process of chromatin reorganization as central to the exploration of the genomic landscape. Accordingly, they advocate the development of agents to limit chromatin structural modification as a chemotherapeutic approach in cancer. We found their theory relevant to understand the phenotypic heterogeneity of malignancy, particularly in familial cancer syndromes. For example, the familial atypical multiple mole melanoma (FAMMM) syndrome, related to a gene mutation, is characterized by a diversity of melanocytic lesions, only some of which become malignant melanoma. This new conceptualization can do much to increase understanding of the diversity of malignancy in families with hereditary cancer. Cancer Res; 76(19); 5602-4. ©2016 AACR.

Indexed as

ChromatinDysplastic Nevus SyndromeGenomicsHumansMelanomaSkin NeoplasmsChromatin

Identifiers

PMID27638875
OpenAlexW2519399904

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.